Innovative Targeting Strategies in Breast Cancer Therapy. Dieser Artikel ist nicht verfügbar.Innovative Targeting Strategies in Breast Cancer Therapy

Innovative Targeting Strategies in Breast Cancer Therapy is a comprehensive reference addressing the challenge of non-specific drug distribution in the body, along with severe toxicity and adverse effects, by offering insights into targeted breast cancer treatment. It further educates researchers on formulating and developing novel carriers with target-specific attributes (such as targeted liposomes, nanoparticles, micelles, and dendrimers), contributing to a more refined approach to breast cancer. This book's content is presented in 12 chapters. The first chapters introduces the reader to the different breast cancer therapies followed by indepth information on targeting . Recognizing the need for targeted drug delivery in breast cancer treatment, this book presents an encompassing compilation of advanced research and formulation strategies. By focusing on effectively targeting cancer cells, the book mitigates dose-related toxicity associated with cytotoxic drugs, providing a comprehensive resource for improved treatment approaches. Research in oncology, pharmacology, medical researchers, biomedical engineers and clinical professionals will find this an essential reference.

Dr. Pankaj Kumar Singh, Ph.D., is an Associate Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research-Hyderabad (NIPER-Hyderabad), India. He earned his Doctorate from CSIR-Central Drug Research Institute, Lucknow. He has authored more than 130 peer-reviewed publications in high-reputation international journals and contributed to over 64 book chapters. He holds 4 granted patents and has 5 patent applications filed on the area of drug delivery. He has supervised 7 PhD students and 38 MS students, and is currently guiding 9 PhD and 6 MS students on their dissertations and research projects. His research focuses on targeted drug delivery to cancer. Dr Singh's lab is actively involved in various scientific and socially impactful projects funded by prestigious organisations, including TSCOST-DBT, CCRUM, DST, ICMR, and the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, Government of India.

Manish K. Chourasia is the Chief Scientist in the Division of Pharmaceutics and Pharmacokinetics at CSIR Central Drug Research Institute (CDRI), Lucknow, India. He has played a significant role in advancing the field of nanoparticle-based drug delivery for breast cancer and neurodegenerative disorders, aiming to enhance the therapeutic outcome.

Kamal Dua is a Professor in the NICM Health Research Institute and the School of Science at Western Sydney University (WSU). Dr Dua has been recognised and named as one of Australia’s Top 250 researchers in 2026, 2025 and 2024 in Research Magazine by “The Australian” in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2026, 2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr Dua’s research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua’s research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.

Dr. Sachin Kumar Singh, is working as professor and head of Pharmaceutical Chemistry and Quality Assurance at School of Pharmaceutical Sciences, Lovely Professional University, India. He is an honorary professor at Australian Research Centre in Complementary and Integrative Medicine (ARCCIM), School of Public Health, University of Technology Sydney, Australia and School of Medical and Life Sciences, Sunway University, 47500 Sunway City, Malaysia. He has 14 years of teaching and research experience. Dr. Singh has completed one DST-SERB funded project on development of SNEDDS of Polypeptide-k for treatment of diabetes mellitus. He has published 500 plus research papers with cumulative impact of 1500 plus, authored 5 books and 25 book chapters. He has 10 granted patents to his credit. He is expert in development of novel drug delivery systems, synbiotics based formulations, analytical and bioanalytical method development and BA-BE studies. He has graduated 17 PhD students and 35 M Pharmacy students and currently graduating 3 masters and 6 PhD students. He is also featured under top 2% scientists of world as per the list of 2021, 2022 and 2023, published by Stanford University, USA. Currently his “h” index is 48 with 11000 plus citations. He is a recipient various national awards including Dr. B.C. Deb memorial award for popularization of science-2020 (honoured by Indian Science Congress Association), Bharat Shiksha Ratan Award-2014 (by Global Society for Health and Educational Growth, Delhi, India) and Bharat Gaurav Puraskar-2022 (by KTK outstanding achievers and education foundation, New Delhi) and Distinguished Alumnus Award (by Sree Siddaganga College of Pharmacy, Tumakuru, Karnataka).

Dr. Kumar Guru is currently at NIPER in Hyderabad. He holds a PhD in pharmaceutical science.His research group mainly focus on basic and applied drug discovery in cancer biology and on role of drug tolerant persistent cell and chemotherapy induced tumor dormancy in cancer. He explores the survival mechanism of these dormant tumors through Autophagy, epigenetic, RNA methylation, efferocytosis, ferroptosis, EMT and YAP/TAZ mechanism.